Lakefront Biotherapeutics NV current report, Q2 FY2021

Business Context and Reporting Period

This Form 6-K filing is submitted by Galapagos NV (not Lakefront Biotherapeutics NV as indicated in metadata) for the month of June 2021, specifically dated June 4, 2021. The registrant is a foreign private issuer headquartered in Mechelen, Belgium, filing under Rule 13a-16 of the Securities Exchange Act of 1934. The filing serves to incorporate a press release (Exhibit 99.1) by reference into the company's Registration Statements on Forms F-3 and S-8.

Financial Metrics

The provided filing text does not contain specific financial data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity within this document. The filing is a procedural submission to distribute a press release rather than a financial report.

Material Changes

The filing text does not disclose specific material changes in financial position or operations. It solely references the issuance of a press release on June 4, 2021, which is attached as Exhibit 99.1. The content of that press release is not included in the provided text, except for a specific exclusion regarding a quote by Dr. Walid Abi-Saab.

Guidance, Outlook, and Risks

No guidance, outlook, management commentary, risks, contingencies, or unusual items are detailed in the provided text. The document functions as a cover sheet to incorporate external information (the press release) into the company's SEC registration statements.

Key Facts for Investor Verification

  • Verify the actual content of the June 4, 2021 press release (Exhibit 99.1) to understand the material event triggering this filing.
  • Confirm the registrant is Galapagos NV, noting the discrepancy with the "Lakefront Biotherapeutics NV" name in the request metadata.
  • Note that a quote by Dr. Walid Abi-Saab contained in the press release is explicitly excluded from incorporation by reference into the Registration Statements.
  • Check the referenced Registration Statements (Forms F-3 and S-8) for the full context of the incorporated information.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.